Linda Goler Blount

Linda Goler Blount

Auto-generated profile, based on publicly available information

Linda Goler Blount

Rare Disease Diversity Coalition, Black Women’s Health Imperative

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Women's Health Issues
Verified
Journal Article
Closed access
LMLois McCloskey
Lois McCloskey
JBJudith Bernstein
Judith Bernstein
LGLinda Goler-Blount
Linda Goler-Blount
AGAnn Greiner
Ann Greiner
ANAnna Norton
Anna Norton
CBChloe E. Bird
Chloe E. Bird

1 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
LMLavanyaa Manjunatha
Lavanyaa Manjunatha
MSM Saundarya
M Saundarya
DDDeepika Dokuru
Deepika Dokuru
NVNisha Venugopal
Nisha Venugopal
JWJenifer Ngo Waldrop
Jenifer Ngo Waldrop
HRHarsha K Rajasimha
Harsha K Rajasimha
Background: Addressing inequities and health disparities for medically underserved populations (MUPs) is critical, as they already face systemic bias and barriers, such as historical mistrust of healthcare systems. To achieve health equity, we need systematic approaches to measuring, quantifying, and reporting diversity, equity, inclusion, and accessibility (DEIA) metrics. Methods: The objective of the study was to analyze literature and clinical trials to summarize the current state of demographics and socioeconomic factors (SF) reporting for MUPs in US-based RD clinical research. PubMed, Cochrane Library, and ClinicalTrials.gov were searched (1983– 2023). A universal set of 30,303 unique RD terms from the Genetic and Rare Diseases Information Center, Orphanet, Rare-X, and ClinicalTrials.gov was used to filter publications and clinical trials. Publications that reported demographics or SFs, were US-based, and involved one or more RDs were included for analysis. Clinical trials that were US-based, involved an RD, and had study results posted were also included. Age, sex or gender, race, ethnicity, and SF data were extracted and analyzed using descriptive statistics. Race and ethnicity data were compared with the US census. The representation of MUPs in RD clinical research was assessed based on the frequency of publications and clinical trials reporting 13 variables. Results: We reviewed 234 publications and 8475 RD clinical trials. Age was the most reported demographic variable (publications: 94%; clinical trials: 100%), followed by sex or gender (86.3%; 100%). Race (50%; 45.7%) and ethnicity (29.9%; 38.5%) were less frequently reported and often in a variable format in publications compared with the ClinicalTrials.gov database. At least one SF was reported in 15.8% of the publications and 0.2% of the trials. American Indian or Native Alaskan, Asian, Hispanic, and Latino participants were significantly underrepresented compared with the US census averages. Data were largely absent for other MUPs: lesbian, gay, bisexual, transgender, and queer or questioning individuals, rural residents, veterans, immigrants, and those affected by disability and poverty. Conclusions: Significant gaps exist in demographics and SF reporting in RD clinical research, and several MUPs are underrepresented. Therefore, a framework to enhance DEIA in RD research is urgently needed.

8 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
LMLavanyaa Manjunatha
Lavanyaa Manjunatha
MSM Saundarya
M Saundarya
NVNisha Venugopal
Nisha Venugopal
JWJenifer Ngo Waldrop
Jenifer Ngo Waldrop
LBLinda Goler Blount
Linda Goler Blount
HRHarsha K Rajasimha
Harsha K Rajasimha
Background: Equitable representation of all populations is crucial for generalizing rare disease (RD) clinical research outcomes, especially given the low prevalence and geographically sparse distribution of patients with RDs. In our companion manuscript ( Current State and Demographic Trends of Medically Underserved Populations in Rare Disease Research , Manjunatha et al. ) we quantified reporting of demographics, socioeconomic factors (SF), and participation trends of medically underserved populations (MUPs) in RD research and clinical trials. Methods: The study builds on the findings of Manjunatha et al ., where we analyzed the reporting of demographics and SF in RD clinical research, here we perform a representation and policy gap analysis of this extracted data. The representation analysis evaluated 13 variables, including age, sex or gender, race, ethnicity, and SF, using four key analyses: reporting statistics, representation, participant distribution, and benchmarking against the US census data. The qualitative policy analysis included existing national and international policies and guidelines. Results: Only age, sex or gender, race, and ethnicity had sufficient data for the representation analysis. While diversity was moderate for these variables, equity, inclusion, and accessibility were low, particularly for racial and ethnic minorities, nonbinary genders, and older adults. Data were insufficient for MUPs such as lesbian, gay, bisexual, transgender, queer or questioning individuals, rural residents, veterans, military spouses, people affected by poverty, and religious minorities. Based on the representation analysis and building upon existing foundational policies and guidelines, we propose three recommendations and a six-pillar framework to mandate and standardize data reporting practices and improve the representation of MUPs in RD clinical research with broader relevance to all clinical research in general. The six pillars are patient advocacy, policy legislation, governmental oversight, standardized data collection and reporting, technological enablement, and global epidemiological research. Conclusions: Addressing the historical underrepresentation of MUPs requires upgrading the foundation of clinical research instead of a piecemeal, siloed approach. This study underscores the systemic gaps in the representation of MUPs in RD research and proposes a six-pillar actionable framework to address these disparities. The systematic implementation of these six pillars can enhance the integrity and outcomes of future RD clinical research.